Searchable abstracts of presentations at key conferences in endocrinology

ea0016p765 | Thyroid | ECE2008

A prospective study on a large series of non toxic multinodular goiters treated with radioiodine: results at long term follow-up

Vannucchi Guia , Mannavola Deborah , Chiti Arturo , Dazzi Davide , Rodari Marcello , Tadayyon Sara , Beck-Peccoz Paolo , Fugazzola Laura

Radioiodine (131I) administration has been found to be effective in the treatment of hyperfunctioning and normofunctioning multinodular goiter. Moreover, lithium therapy has been shown to enhance the radioiodine efficacy and to reduce the transient thyrotoxicosis induced by radioiodine.Aim of the present study was to evaluate the long term efficacy of 131I with or without lithium administration in the treatment of non toxic multinod...

ea0014oc1.4 | Thyroid clinical | ECE2007

A novel tyrosine-kinases selective inhibitor with anti-tumoral efficacy (Sunitinib) induces a block in iodine uptake and transient hypothyroidism

Mannavola Deborah , Vannucchi Guia , Carletto Marco , Longari Virgilio , Bertuelli Rossella , Coco Paola , Casali Paolo , Beck-Peccoz Paolo , Fugazzola Laura

Sunitinib (SU11248) is a multitarget inhibitor of tyrosine-kinases (RTK) recently tested in clinical trials for the treatment of some human cancers. Side effects are mostly represented by asthenia and appear in a dose and time correlated manner. After the unexpected observation of a myxedematous coma in a patient affected with GIST and treated with Sunitinib, we evaluated the effect of this drug on thyroid function in 24 patients treated for GISTs Imatinib resistant. Patients ...

ea0014p109 | (1) | ECE2007

Histopathological and molecular studies in patients with goiter and hypercalcitoninemia: reactive or neoplastic C-cell hyperplasia?

Verga Uberta , Ferrero Stefano , Vicentini Leonardo , Brambilla Tatiana , Cirello Valentina , Muzza Marina , Beck-Peccoz Paolo , Fugazzola Laura

The cut-off values able to differentiate between reactive or neoplastic C cell hyperplasia (CCH) or to predict sporadic medullary thyroid cancer (MTC) are still debated both for basal and stimulated calcitonin (bCT and sCT). Aim of the present study was to define the prevalence and the histological patterns of CCH in 15 patients with multinodular goiter (MNG), bCT>10 pg/ml and sCT levels >50 pg/ml. These data were compared with those from 16 patients with MNG and bCT l...

ea0011p480 | Endocrine tumours and neoplasia | ECE2006

An in-frame complex germline mutation in the juxtamembrane intracellular domain causing RET activation in familial medullary thyroid carcinoma

Fugazzola L , Cordella D , Muzza M , Alberti L , Travaglini P , Colombo P , Beck-Peccoz P , Persani L

Activating mutations of the RET proto-oncogene, encoding a tyrosine kinase receptor, are associated with inherited syndromes, MEN2A and MEN2B, and with both familial and sporadic medullary thyroid cancer (MTC). Single base-pair missense mutations in the extracellular cysteine-rich domain are responsible for the majority of MEN2A and familial MTC (FMTC) cases. Rarely, somatic deletions and germline duplications of variable segments of the gene have been reported in spora...

ea0011p857 | Thyroid | ECE2006

A novel test with recombinant human TSH for the differential diagnosis of congenital hypothryoidism in pediatric age

Fugazzola L , Weber G , Mannavola D , Vannucchi G , Carletto M , Longari V , Persani L , Beck-Peccoz P

Congenital hypothyroidism (CH) affects 1:2.000–3.000 newborns. In most cases, the cause is a developmental defect (dysgenesia) or an arrested migration (ectopia) of the thyroid gland. In the remaining cases TSH resistance or defects in iodide transport or thyroid hormonogenesis account for CH. The differential diagnosis is aimed to recognize permanent CH forms and to achieve an etiologic diagnosis for accurate management and genetic counselling. Appropriate investigations...

ea0045oc5.7 | Oral Communications 5- Endocrine | BSPED2016

Frequent occurrence of DUOX2 and DUOXA2 mutations in cases with borderline bloodspot screening TSH who develop ‘True’ congenital hypothyroidism

Peters Catherine , Nicholas Adeline K. , Lyons Greta , Langham Shirley , Serra Eva G. , Schoenmakers Erik , Muzza Marina , Fugazzola Laura , Schoenmakers Nadia

The UK newborn screening programme for congenital hypothyroidism (CH) facilitates prevention of neurodevelopmental delay in CH by enabling prompt diagnosis and treatment. Although the UK Newborn Screening Programme Centre (UKNSPC) defines a borderline bloodspot screening TSH (bsTSH) concentration as 10–20 mU/l, the lower cutoff used at Great Ormond Street Hospital (6 mU/l), enables diagnosis of true and transient CH in cases missed using UKNSPC criteria. We hypothesised t...

ea0092ps1-09-05 | Thyroid Cancer | ETA2023

Inactivating mutations of TP53 and resistence to tyrosine-kinase inhibitors in patients affected with aggressive thyroid cancer

Cirello Valentina , Colombo Carla , Manzo Alessandro , Tosi Delfina , Gianelli Umberto , Gazzano Giacomo , Ferrero Stefano , Persani Luca , Fugazzola Laura

Objectives: Well differentiated thyroid cancers (WDTC) are generally sensitive to first line treatments or eventually to tyrosine kinase inhibitors (TKIs). However, a part of WDTC together with poorly differentiated (PDTC) and anaplastic (ATC) thyroid cancers are particularly aggressive and refractory to all treatments, TKIs included. Since TKIs resistance is proven to be related with the presence of TP53 mutations in other tumours, and TP53 alterations are f...

ea0092ps2-11-09 | Miscellaneous 2 | ETA2023

Thyroid dysfunctions in covid-19 patients: impact on in-hospital outcomes and long-covid symptoms

Campi Irene , Lugaresi Marina , Battista Perego Giovanni , Fratianni Gerardina , Balla Eva , Bulgarelli Ilaria , Persani Luca , Fugazzola Laura

Context: A variety of thyroid disorders have been documented in COVID-19 patients, including non-thyroidal illness syndrome (NTIS), subacute thyroiditis (SAT) and thyrotoxicosis.Objectives: To investigate the relationship between thyroid dysfunctions observed during hospitalisation and COVID-19-related morbidity and mortality.Study design and setting: Prospective cohort study on patients admitted in a tertiary hospital for COVID-19...

ea0092ps2-16-07 | Thyroid Cancer clinical 2 | ETA2023

Tumor lysis syndrome during neoadjuvant selpercatinib treatment for medullary thyroid cancer

Trevisan Matteo , De Leo Simone , Vanessa Re Sarto Giulia , Moneta Claudia , Pirovano Marta , Colombo Carla , Cosmai Laura , Fugazzola Laura

Selpercatinib is a specific RET inhibitor, highly effective in the treatment of advanced RET-mutant medullary thyroid carcinoma (MTC). The consequences of selpercatinib administration in MTC patients who have not undergone thyroid surgery are still unknown. We report the case of an 84-year-old man undergoing investigations for worsening diarrhea and weight loss. Upon a neck ultrasound scan and blood exams that pointed out high levels of both calcitonin (CT, 20.583 ng/l) and ca...

ea0092ps2-17-02 | Thyroid Cancer Diagnosis 2 | ETA2023

Monocentric validation of the ’thyroid risk score’ (TRS) in a large series of indeterminate thyroid nodules

Muzza Marina , Colombo Carla , Vannucchi Guia , Succi Massimiliano , Palazzo Sonia , Frattini Francesco , Gentilini Davide , Gazzano Giacomo , Persani Luca , Fugazzola Laura

The diagnosis of indeterminate thyroid nodules is a challenge in cytopathology practice. To increase the diagnostic accuracy in these cases, we previously set up a ’thyroid risk score’ (TRS), derived from the sum of the scores assigned to: cytology + EU-TIRADS classification + nodule size + molecular profile. In the present study we prospectively validated the reliability of the TRS in the clinical practice. From 2018 to 2022 we evaluated 354 indeterminate nodules (2...